Study of the Discriminating Power of a Blood Biomarker for Omega-3 Polyunsaturated Fatty Acid Content of the Retina for Age-related Macular Degeneration (AMD)
NCT ID: NCT04278300
Last Updated: 2020-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
205 participants
OBSERVATIONAL
2020-02-11
2020-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Age-related macular degeneration has two clinical forms:
* Atrophic or dry form: progressive disappearance of photoreceptors, alteration of the pigmentary epithelium leading to a thinning of the macula.
* Exudative or humid form: development of immature choroidal neo-vessels, leading to the formation of edema or intra or sub-retinal hemorrhage at the origin of the symptoms.
There are still many questions about the pathogenesis of age-related macular degeneration, and there is currently no etiological treatment. The disorder is thought to have a multifactorial, genetic and environmental origin.
Among the environmental risk factors, dietary intake of omega-3 polyunsaturated acids and its effect on the retina are factors that influence both the incidence and progression of the disease. However, intervention studies have not been able to demonstrate the preventive value of omega-3 polyunsaturated fatty acids. It is likely that the precise identification of patients who could benefit from this supplementation is necessary. Currently, the estimation of dietary intake of omega-3 polyunsaturated fatty acids is based on dietary surveys, which implies a number of limits. A blood biomarker of omega-3 polyunsaturated fatty acid content in the retina has been previously identified, which if lowered may be a risk factor for age-related macular degeneration. A low level could also help to identify patients who would best respond to supplementation. A publication has been submitted and a patent has been filed for this biomarker. The objective of this project is to confirm the relationship between this biomarker and the presence of age-related macular degeneration. The analysis will be refined by correlating the discriminating character of the biomarker with factors that may influence the intestinal metabolism of dietary lipids and their bioavailability in the blood. For this purpose, the status of the subjects with regard to their intestinal flora (microbiota) will be evaluated. The relationship between lipid metabolism, microbiota and age-related macular degeneration should also provide a better understanding of the pathophysiological mechanisms that link diet, lipid metabolism and age-related macular degeneration.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case
patient with age-related exudative macular degeneration
blood sampling
dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
faecal sampling (optional)
analysis of the microbiota by DNA sequencing
control
Patient with no macular disorder and in need of cataract surgery
blood sampling
dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
faecal sampling (optional)
analysis of the microbiota by DNA sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling
dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
faecal sampling (optional)
analysis of the microbiota by DNA sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject aged 50 years or older
* Subject with exudative AMD or
* Subject with macular disorder requiring cataract surgery
Exclusion Criteria
* Protected adults (curatorship, guardianship)
* Persons deprived of their liberty by judicial or administrative decision
* Adult unable to express consent
* Subject who has already participated in the study
* Subject with pre-existing maculopathy not labelled AMD
* Subject refusing blood sample
* Subject with diabetes
* Subject on antibiotics or having had an antibiotic treatment in the last 3 months
* Subject with a BMI \< 18.5 or \> 30 kg/m2
* Subject with extreme eating habits (veganism, bulimia, anorexia)
* Subject currently on a diet with avoidance of certain types of food or a low-calorie diet
* Subject with an inflammatory disease (especially digestive disease)
* Subject having undergone bariatric surgery
* Subject having digestive tract malformations
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CREUZOT 2019
Identifier Type: -
Identifier Source: org_study_id